From the Hypotheses to Clinical Evidence in Retinal Therapy
The off-label, therapeutic use of intravitreal bevacizumab (IVB) in vascular retinal diseases such as diabetic macular edema and proliferative diabetic retinopathy (PDR) has increased significantly due to its ability to reduce retinal neovascularization and slow progression of disease. Here, we will...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Knowledge E
2021-05-01
|
Series: | Journal of Ophthalmic & Vision Research |
Subjects: | |
Online Access: | https://doi.org/10.18502/jovr.v16i2.9092 |